enGene Therapeutics downgraded by Guggenheim
$ENGN
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Guggenheim downgraded enGene Therapeutics from Buy to Neutral
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 6/18/2026 | Equal-Weight → Underweight | Morgan Stanley | |
| 5/8/2026 | $4.00 | Strong Buy → Outperform | Raymond James |
| 5/8/2026 | $4.00 | Overweight → Neutral | Piper Sandler |
| 5/8/2026 | Buy → Neutral | Guggenheim | |
| 5/8/2026 | Mkt Outperform → Mkt Perform | Citizens | |
| 5/8/2026 | $2.00 | Outperform → Market Perform | Leerink Partners |
| 5/8/2026 | $2.00 | Overweight → Equal Weight | Wells Fargo |
| 5/8/2026 | Overweight → Equal-Weight | Morgan Stanley |
8-K - enGene Therapeutics Inc. (0001980845) (Filer)
8-K - enGene Therapeutics Inc. (0001980845) (Filer)
8-K/A - enGene Therapeutics Inc. (0001980845) (Filer)
Michael Heffernan assumes the role of Chairman of the Board Dr. Richard Glickman to step down Pre-Biologics License Application (BLA) meeting with the FDA planned for 2H 2026 Initiation of BLA submission for detalimogene planned for 2H 2026 Potential FDA approval of detalimogene in 2027 enGene Therapeutics Inc. (NASDAQ:ENGN, "enGene" or the "Company")), a clinical-stage, non-viral genetic medicines company, today announced changes to its Board of Directors as it plans for potential regulatory milestones and to support commercial readiness for detalimogene voraplasmid ("detalimogene") if approved. Detalimogene is being evaluated in the ongoing, open-label, multi-cohort, Phase 2 LEG
The appointment comes as Rectify transitions into a clinical-stage company following the recent initiation of the Phase 1 study of RTY-406, its lead program for hepatobiliary diseases.Rectify is developing oral medicines designed to rectify the dysfunction of membrane bound proteins, with the goal of treating the underlying cause of serious diseases rather than simply managing symptoms. CAMBRIDGE, Mass., July 15, 2026 (GLOBE NEWSWIRE) -- Rectify Pharmaceuticals, a biotechnology company advancing Positive Functional Modulators (PFMs), a novel class of oral small molecules designed to restore and enhance membrane protein function, today announced the appointment of Constantine Chinoporos as
12-month complete response data from LEGEND pivotal cohort and subsequent FDA engagement planned for 2H 2026 Initiation of Biologics License Application (BLA) filing for detalimogene planned for 2H 2026 First patients enrolled in surfactant plus detalimogene cohort Approximately 50% reduction in force to streamline operations and preserve cash to focus on BLA and precommercial activities Well capitalized with cash, cash equivalents and marketable securities of $285 million enGene Therapeutics Inc. (NASDAQ:ENGN, "enGene" or the "Company")), a clinical-stage, non-viral genetic medicines company today announced its financial results for the second quarter ended April 30, 2026, and pr
4 - enGene Holdings Inc. (0001980845) (Issuer)
4 - enGene Holdings Inc. (0001980845) (Issuer)
4 - enGene Holdings Inc. (0001980845) (Issuer)
4 - enGene Therapeutics Inc. (0001980845) (Issuer)
4 - enGene Therapeutics Inc. (0001980845) (Issuer)
4 - enGene Therapeutics Inc. (0001980845) (Issuer)
Morgan Stanley downgraded enGene Therapeutics from Equal-Weight to Underweight
Raymond James downgraded enGene Therapeutics from Strong Buy to Outperform and set a new price target of $4.00
Piper Sandler downgraded enGene Therapeutics from Overweight to Neutral and set a new price target of $4.00
The appointment comes as Rectify transitions into a clinical-stage company following the recent initiation of the Phase 1 study of RTY-406, its lead program for hepatobiliary diseases.Rectify is developing oral medicines designed to rectify the dysfunction of membrane bound proteins, with the goal of treating the underlying cause of serious diseases rather than simply managing symptoms. CAMBRIDGE, Mass., July 15, 2026 (GLOBE NEWSWIRE) -- Rectify Pharmaceuticals, a biotechnology company advancing Positive Functional Modulators (PFMs), a novel class of oral small molecules designed to restore and enhance membrane protein function, today announced the appointment of Constantine Chinoporos as
Bladder cancer development leader who helped drive recent FDA product approval in NMIBC joins to lead research and development strategy Appointment strengthens enGene's clinical development and regulatory capabilities ahead of planned 2H 2026 BLA submission for detalimogene enGene Holdings Inc. (NASDAQ:ENGN, "enGene" or the "Company")), a clinical-stage, non-viral genetic medicine company, today announced that Hussein Sweiti, M.D., MSc, was appointed Chief Medical Officer, effective September 29, 2025. Dr. Sweiti is a surgical oncologist and physician-scientist with more than 15 years of experience spanning clinical practice, oncology clinical research, global drug development, regula
Philip Astley-Sparke, William Grossman and Michael Heffernan join the Board Management promotions strengthen clinical and regulatory operations Matthew Boyd named Chief Regulatory Officer, Jill Buck Chief Development Officer, and Katherine Chan Executive Director, Urology Clinical Lead enGene Holdings Inc. (NASDAQ:ENGN), a clinical-stage, non-viral gene-based immunotherapy company, today announced the appointment of three new members to its Board of Directors: Philip Astley-Sparke, William Grossman, M.D., Ph.D., and Michael Heffernan, R.Ph. Their combined experience across gene therapy, oncology, clinical development, and global product launches will support enGene's strategic transit
SC 13G/A - enGene Holdings Inc. (0001980845) (Subject)
SC 13G/A - enGene Holdings Inc. (0001980845) (Subject)
SC 13G/A - enGene Holdings Inc. (0001980845) (Subject)
12-month complete response data from LEGEND pivotal cohort and subsequent FDA engagement planned for 2H 2026 Initiation of Biologics License Application (BLA) filing for detalimogene planned for 2H 2026 First patients enrolled in surfactant plus detalimogene cohort Approximately 50% reduction in force to streamline operations and preserve cash to focus on BLA and precommercial activities Well capitalized with cash, cash equivalents and marketable securities of $285 million enGene Therapeutics Inc. (NASDAQ:ENGN, "enGene" or the "Company")), a clinical-stage, non-viral genetic medicines company today announced its financial results for the second quarter ended April 30, 2026, and pr
54% complete response (CR) rate at any time; 43% six‑month CR rate Low rate of progression to muscle-invasive or higher disease (3.2%) Low percentage of patients experienced treatment-related adverse events (TRAEs) (55%), nearly all of which were mild Low percentage of patients experienced TRAEs leading to treatment interruption (2.4%) or discontinuation (2.4%) Kaplan-Meier estimate of 12-month CR rate is 25% enGene to host webcast to discuss results today, May 7, 2026, at 8:00 a.m. ET enGene Therapeutics Inc. (NASDAQ:ENGN), a clinical-stage, non-viral genetic medicines company, today reported additional interim results from the pivotal cohort of its ongoing, Phase 2 LEGEND t
Low rates of treatment-related adverse events (42%) and dose interruptions (1.6%) Emerging detalimogene profile supports potential first line use in patients with high-risk, BCG-unresponsive non-muscle invasive bladder cancer with CIS LEGEND trial pivotal cohort completed enrollment with 125 patients, exceeding target enGene to host conference call and webcast at 8:00 a.m. ET enGene Holdings Inc. (NASDAQ:ENGN), a clinical-stage, non-viral genetic medicines company, today reported additional preliminary data from the pivotal cohort of its ongoing, Phase 2 LEGEND trial of detalimogene voraplasmid (also known as detalimogene and previously EG-70) in high-risk, Bacillus Calmette-Guérin